Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease. - Wikidata - awgldk - TriplyDB

Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.

Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.

http://www.wikidata.org/entity/Q35058359

about

Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Neuroprotective Effects of A Standardized Flavonoid Extract of Safflower Against Neurotoxin-Induced Cellular and Animal Models of Parkinson's Disease.Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.Basic science breaks through: New therapeutic advances in Parkinson's disease.Development of Passive Immunotherapies for Synucleinopathies.Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals.Gene therapy targeting mitochondrial pathway in Parkinson's disease.AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models.Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.Animal models of α-synucleinopathy for Parkinson disease drug development.A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.Vaccination strategies in tauopathies and synucleinopathies.Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention

P2860

Q26781130-CBCDB7F7-7621-4D4C-8E60-0AF48842C7BF Q33701172-D2B421E1-EE00-49C4-8B99-6CB9057DB2B6 Q35958725-354A1BA8-F955-445A-A9BC-BF4F0C09F5AE Q36474039-0CA00479-B290-499E-8555-991FF3E6B71B Q36484413-FC659D5A-C4E9-4421-893A-917B8D616F84 Q36611143-C31305AD-3172-4C0D-B4B2-E94360252BAA Q36672116-D42B2A3E-2FDC-427B-AB0C-C38730FFC266 Q38540633-B84622A7-2005-4E82-BC5B-430A0A642263 Q38547662-1A97047E-08CB-460B-8397-CCD4F90DD1BC Q38679627-1EF82731-58E4-498F-905E-44B1459A42B4 Q38817063-E1AFCBD2-1FA3-4D2A-AA52-1536399E7CAD Q38942195-8C364042-5990-4CB5-A5C7-D942C149C6EF Q38957332-1DC82E08-B852-4D74-AB00-6FF38D52A80A Q39139260-90F51BBA-F3C0-4900-A3DC-D0F2DF8D4032 Q40087267-BCF143CD-52D2-4DD7-A31C-A2F28A5BB34F Q40106906-DB247E82-D31C-44D2-821C-E0D87474D51C Q41069719-724F50CF-9F61-4ED3-82F1-96F4ABCD8402 Q41117719-672EF469-AFC8-47C3-8F9A-88A332D4E734 Q45873810-0B4FF470-7F1B-4514-8FE3-FFCAD6DD52BF Q47563994-F1EF4D7B-8841-4999-87B0-261171BE192C Q47860105-7676C302-6627-4882-85E6-C76B797CB755 Q58793525-B2D0E623-D7E3-4E65-8668-B083ED58448A Q58799080-8DB98451-8A64-44D9-B85B-F81CD435CB98

P2860

Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.

http://www.wikidata.org/entity/Q35058359

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anti-human α-synuclein N-termi ...... model of Parkinson's disease.

@ast

Anti-human α-synuclein N-termi ...... model of Parkinson's disease.

@en

type

label

Anti-human α-synuclein N-termi ...... model of Parkinson's disease.

@ast

Anti-human α-synuclein N-termi ...... model of Parkinson's disease.

@en

prefLabel

Anti-human α-synuclein N-termi ...... model of Parkinson's disease.

@ast

Anti-human α-synuclein N-termi ...... model of Parkinson's disease.

@en

P1433

Q35058359-F932FC48-1A4E-4B01-B6AC-3D5655DC27DC

P1476

Q35058359-76530FAA-FBF1-4BA8-95AF-2DBF02ACD648

P2093

Q35058359-21B8B873-5703-4D45-B327-589DB44D1D8F

Q35058359-488441B9-BCA5-41E0-876D-F5ED266536E2

Q35058359-59E66650-4942-4904-A306-B6961A59D291

Q35058359-5E7C2E3B-74F8-4ECF-A047-206B6A3BD260

Q35058359-A7C0ABD8-847A-457B-9EAB-6847A03200B5

Q35058359-A95FB7E2-D8C5-4B41-BEAA-907E847C5354

Q35058359-B843892E-1ACF-4E1D-897D-8052D6E3C61B

Q35058359-BB9DA903-4C3E-4951-A1AB-F8478AC50012

Q35058359-E3A28851-5D60-4F2E-B968-91154C26F570

Q35058359-EB9253AB-52C0-4DC6-A7BF-B82E11DB2597

P2860

Q35058359-00339796-8FA9-440C-9F1F-FC09616DCD86

Q35058359-028C0B64-B6E4-4E65-9451-499F2FC9625A

Q35058359-03C1FA6C-869C-441F-A239-8D12ED2415CD

Q35058359-0899CBB9-25F3-472C-B5A2-AF0BDCBD80BD

Q35058359-0E28585A-8150-41C5-A9D1-5090F4C6DF9D

Q35058359-2BDD11F7-152E-40CF-8409-0D48792AABC3

Q35058359-2E107F15-46D6-4E6E-B134-B08D3FC2DD6A

Q35058359-321AE75D-AF96-476F-8BC8-B318EB14A79B

Q35058359-332B5DBF-E921-49D2-B057-E30D689F7616

Q35058359-3436DD2D-0E01-4290-9A7A-0922BF06851F

P304

Q35058359-59A8049A-9DDC-416D-B7A4-042DF01AE4F7

P31

Q35058359-95BFDB62-F9E7-4CCD-8B9D-27D62F085177

P356

Q35058359-E5C24FDE-F2F5-4AA7-B7FD-98CF2D47C73A

P407

Q35058359-ABAF2ED2-9E2B-4B90-A544-89B8C01B9737

P433

Q35058359-9A295E3A-CAE6-436D-9C77-84A93A1C8E05

P478

Q35058359-27189463-A8C3-436C-8438-0485072B8E1B

P50

Q35058359-D99E3BE9-8BA6-4E02-A3E4-21F09C8EA819

P577

Q35058359-7BCDF2CA-2832-4E2E-8FD3-4A4BD4D910A9

P5875

Q35058359-0740483C-12CA-4E47-9A65-13E058CFBB4A

P698

Q35058359-93AB23F1-2061-495E-9843-26BA9C7D59A4

P921

Q35058359-149542DE-AD5D-441D-956F-3D14B9DDB174

Q35058359-733A8555-76DA-4EBB-8792-51C84A6CAA32

P932

Q35058359-4953AE24-6853-4FFB-94A3-20A43843E566

P356

JOURNAL.PONE.0116841

P1433

P1476

Anti-human α-synuclein N-termi ...... model of Parkinson's disease.

@en

P2093

Bethany Grimmig

http://www.w3.org/2001/XMLSchema#string

Charles Hudson

http://www.w3.org/2001/XMLSchema#string

Chuanhai Cao

http://www.w3.org/2001/XMLSchema#string

Ge Bai

http://www.w3.org/2001/XMLSchema#string

Hui Liu

http://www.w3.org/2001/XMLSchema#string

Kenneth E Ugen

http://www.w3.org/2001/XMLSchema#string

Kevin Nash

http://www.w3.org/2001/XMLSchema#string

Masroor Sharif

http://www.w3.org/2001/XMLSchema#string

Md Shahaduzzaman

http://www.w3.org/2001/XMLSchema#string

Xiaoyang Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease

Immunotherapy for Alzheimer's disease: hoops and hurdles

Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device.

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer

Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.

The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast.

P304

e0116841

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0116841

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273953975

http://www.w3.org/2001/XMLSchema#string

P698

25658425

http://www.w3.org/2001/XMLSchema#string

P921

P932

4319932

http://www.w3.org/2001/XMLSchema#string